Plexium Australia

Plexium is a pharmaceutical company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company utilizes a proprietary high-throughput, cell-based screening platform designed to identify molecular glues and E3 ligase modulators that can target previously undruggable proteins. By conducting screens in a physiological cellular environment, Plexium can discover small molecules that induce the degradation of disease-causing proteins with high specificity. The company's pipeline is primarily focused on oncology and neurodegenerative diseases, supported by major strategic collaborations with industry leaders such as Amgen and AbbVie. Plexium Australia serves as a regional subsidiary supporting the company's global research and development operations.